The Institute for Clinical and Economic Review has published its assessment of JAK inhibitors for treating rheumatoid arthritis.
Studies show oral semaglutide is effective in treating type 2 diabetes. ICER's report will help insurance companies block access for patients in need.
Patients Rising Now is welcomes the opportunity to provide recommendations and comments about the pros and cons of ICER’s August 21st document outlining proposed changes to its Value Assessment Framework’s…
Institute for Patient Access & Affordability (IPAA) is a new program division of Patients Rising with the mission to provide patient-powered pathways to help both public and private payers as…
The Institute for Clinical and Economic Review, which receives support from insurance companies, has begun its financial analysis of how two new SCD treatments, crizanlizumab and voxelotor, will affect insurance profits.
SSTs are considered game changers in medicine with the potential to cure rare, fatal or chronic diseases, such as Alzheimer’s disease.
Massachusetts state representatives, have introduced legislation that would block insurance companies, hospitals, health maintenance organizations, and the state’s Medicaid program, MassHealth, from using “quality-adjusted life years” in providing care to patients.
The Institute for Clinical and Economic Review will conduct an insurance profit analysis for two new additive therapies cardiovascular disease.
Patients Rising NOW offers the following comments on ICER’s May 22nd draft report, “Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy.” Our comments about the draft report are organized below…
Their kids have a rare and fatal disease. ICER President Dr. Steve Pearson believes Duchenne moms shouldn't get a "vote" on their kids' treatment.